Peptide fact checks.

FDA's detailed chemical record lists ropocamptide as a peptide with 37 amino acids. This record does not show product quality or human benefit.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

FDA identity records for LL-37 and ropocamptide; this does not establish the identity or quality of an online product.

The first 34-person leg-ulcer study reported possible benefit. A later study assigned 149 people to LL-37 or placebo. Of those people, 148 received a study treatment. It found no clear benefit for the full group. A 25-person diabetic-foot-ulcer study found a limited sign of new tissue growth, but no clear changes in other measures. These results do not prove general wound healing.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The reviewed venous-ulcer studies and small diabetic-foot-ulcer study; results apply only to their defined products, groups, wound types, and follow-up periods.

The 238-person study used an engineered bacterium that made a lab-produced form of LL-37. Patients and researchers knew which treatment was given. The study took place at one medical center. It did not test a standard LL-37 vial, spray, or plain peptide product.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The engineered bacterium used in the study and the one-center setting; this does not establish results for other LL-37 materials.

No FDA-approved U.S. LL-37 drug was found when Drugs@FDA was checked for LL-37 and ropocamptide on August 30, 2026. An FDA chemical record identifies a substance. It does not mean that FDA approved a drug.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States approval status as reviewed August 30, 2026.

The person or group who asked FDA to consider LL-37 for its pharmacy-compounding list withdrew the request. That request was called a 503A nomination. Its withdrawal is not a ban. The current federal rule does not list LL-37. FDA plans an advisory-committee discussion before the end of February 2027. That discussion is not a final decision or drug approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The U.S. pharmacy-compounding status as reviewed August 30, 2026; an advisory discussion is not a final FDA action.

FDA has separate records for ropocamptide (LL-37) and LL-37 amide. An online product name does not prove the same chemical form, amino-acid order, purity, or quality.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

FDA identity records and online product names; this is not advice on how to use a product.

Yes. FDA lists P21 and P021 as names for the P-21 chemical record. This name match does not prove that a sold product has the same contents or quality.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The FDA chemical identity record; this does not establish drug approval, product quality, or human benefit.

Yes. Studies reported learning or memory findings in normal mice and in mouse models of Alzheimer-like disease. Results in mice do not prove a benefit in people.

What this answer is based on

Cell, animal, or other lab research
This answer uses research in cells, animals, or other settings outside patient care. It does not show a benefit in people.

Applies to

Normal adult mice and genetically changed mouse models; not people with memory problems or Alzheimer’s disease.

The reviewed studies used mice, rats, or cells. The P021 registry search found no study in people. Animal or cell findings cannot show that P21 treats people.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Memory or Alzheimer’s disease outcomes in people who received a verified P21 study product.

FDA says a Unique Ingredient Identifier, or UNII, helps identify a substance. It does not mean that FDA reviewed or approved a drug. No FDA-approved P21 product was found under the reviewed names.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States drug-approval status as checked for P21, P021, and P-21 on August 30, 2026.

No. P21 peptide is a small compound made in a lab. CDKN1A is a human gene. It makes a protein also called p21. The shared short name does not make them the same.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

P21 peptide identity compared with the human CDKN1A gene and p21 protein.

The P021 registry search found no study in people. Animal studies cannot set a safe amount, rule out uncommon harm, or show long-term safety for people.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

People exposed to a verified P21 study product, with enough follow-up to assess harms.

The discovery report identifies a 28-residue intestinal peptide. This identity fact does not establish a human treatment.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The natural vasoactive intestinal peptide, not a finished drug product.

A study of 12 healthy volunteers measured a short vascular response and delayed headache after a specified infusion. It did not test a disease treatment.

What this answer is based on

Studies of body changes in people
This answer uses a study of how the substance enters or changes the body in people. This alone does not show a health benefit.

Applies to

The 12-person healthy-volunteer study and its exact research route.

The 196-person randomized trial did not meet its prespecified day-60 primary endpoint. Secondary and subgroup results cannot make the primary endpoint significant.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Intravenous aviptadil in the 2022 trial; no inference about another VIP product.

A substance record identifies a substance. The two checked FDA orphan records state that the named orphan indications were not approved. Neither record approves a finished product.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The exact FDA records checked September 12, 2026; this is not a complete product-level approval search.

The cited trial studied defined intravenous research material. The checked FDA records do not establish the identity, quality, route, or equivalence of another product.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Online and compounded products compared with the 2022 trial material.